Skip to main content
. 2019 Oct 7;2019(10):CD004052. doi: 10.1002/14651858.CD004052.pub2

11. Adverse events ‐ valproate vs placebo (children and adolescents).

Adverse effect Odds ratio; 95% CI; heterogeneity; N of studies, N of participants P value
Abdominal pain OR 3.74, 95% CI 0.62 to 22.59; I2 = 0%; 2 studies, 178 participants P = 0.15
Ammonia increased OR 9.25, 95% CI 0.49 to 174.87; 1 study, 150 participants P = 0.14
Excitement OR 1.92, 95% CI 0.08 to 44.92; 1 study, 28 participants P = 0.68
Difficulty concentrating OR 0.01, 95% CI 0.00 to 0.15; 1 study, 28 participants P = 0.002
Difficulty waking in the morning OR 0.10, 95% CI 0.00 to 2.78; 1 study, 28 participants P = 0.18
Dyspepsia (Indigestion) OR 5.00, 95% CI 0.24 to 105.93; 1 study, 150 participants P = 0.30
Enuresis Not estimable N/A
Gastritis OR 9.25, 95% CI 0.49 to 174.87; 1 study, 150 participants P = 0.14
Headache OR 1.07, 95% CI 0.44 to 2.61; I2 = N/A; 2 studies, 178 participants P = 0.88
Initial insomnia Not estimable N/A
Irritability Not estimable N/A
Nausea OR 0.13, 95% CI 0.02 to 1.06; 1 study, 150 participants P = 0.06
Outburst of anger OR 6.29, 95% CI 0.31 to 127.06; 1 study, 28 participants P = 0.23
Pharyngitis streptococcal OR 7.10, 95% CI 0.36 to 139.78; 1 study, 150 participants P = 0.20
Pharyngolaryngeal pain OR 0.48, 95% CI 0.04 to 5.41; 1 study, 150 participants P = 0.55
Rash OR 4.06, 95% CI 0.44 to 37.17; 1 study, 150 participants P = 0.22
Nasal congestion OR 0.38, 95% CI 0.06 to 2.37; I2 = 0%; 2 studies, 178 participants P = 0.30
Sedation OR 0.40, 95% CI 0.12 to 1.37; 1 study, 150 participants P = 0.14
Sadness OR 0.42, 95% CI 0.05 to 3.22; 1 study, 28 participants P = 0.40
Somnolence OR 5.14, 95% CI 0.59 to 45.10; 1 study, 150 participants P = 0.14
Upper respiratory tract infection OR 0.97, 95% CI 0.06 to 15.85; 1 study, 150 participants P = 0.98
Vomiting OR 1.72, 95% CI 0.59 to 4.99; 1 study, 150 participants P = 0.32
Weight increase OR 1.97, 95% CI 0.18 to 22.24; 1 study, 150 participants P = 0.58